WXXWY (WuXi Biologics (Cayman)) EPS (Basic): $0.34 (TTM As of Dec. 2025)


WXXWY WuXi Biologics (Cayman) Inc WXXWY
97 GF Score
Price $8.42
GF Value $9.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) EPS (Basic)?

WuXi Biologics (Cayman) WXXWY +3.57% 97 EPS (Basic) is $0.34 as of Dec. 2025. GuruFocus rates WXXWY with a GF Score™ of 97/100 and a GF Value™ of $9.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.34.

WuXi Biologics (Cayman)'s EPS (Diluted) for the six months ended in Dec. 2025 was $0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.33.

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Dec. 2025 was $0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.38.

During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRIGrowth Rate was 22.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 5.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 49.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, WuXi Biologics (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 138.10% per year. The lowest was 5.20% per year. And the median was 55.80% per year.

WuXi Biologics (Cayman)  (OTCPK:WXXWY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

WuXi Biologics (Cayman) EPS (Basic) Related Terms

WuXi Biologics (Cayman) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) EPS (Basic) Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.30 0.23 0.23 0.35

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.10 0.12 0.16 0.18
WXXWY
97GF Score
WuXi Biologics (Cayman) Inc WXXWY
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

WuXi Biologics (Cayman)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(696.891-0)/2013.727
=0.35

WuXi Biologics (Cayman)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(364.76-0)/2014.393
=0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.34 mean?
WuXi Biologics (Cayman) (WXXWY) has a EPS (Basic) of $0.34 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s EPS (Basic) too high?
WuXi Biologics (Cayman)'s current EPS (Basic) is $0.34. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s EPS (Basic) compare to VRTX and REGN?
WuXi Biologics (Cayman)'s EPS (Basic) of $0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current EPS (Basic) is $0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXXWY) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.71, compared to a current price of $8.42 — trading 13.3% below its estimated fair value. The current EPS (Basic) is $0.34. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXXWY), the current EPS (Basic) is $0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXXWY) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $8.42 is trading 13.3% below its estimated GF Value™ of $9.71. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXXWY:

  • EPS (Basic): $0.34
  • GF Value™: $9.71 vs. price of $8.42 (13.3% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXXWY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXXWY

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.42
Price
$9.71
GF Value